Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07281014 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing

Name: Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing — clinical trial record (NCT07281014)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 4

SponsorYale University

Started2026-01-27

View on ClinicalTrials.gov ↗

Amendment history

2026-08-24

Study Status, Study Design, Contacts/Locations v2

Enrollment closed, study ongoing

Enrollment targetestimated 20→confirmed 21

Study sitesdetails revised at 1 of 1 site

2026-02-16

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2026-01→confirmed 2026-01-27

Study sitesdetails revised at 1 of 1 site

2025-12-03

Original filing

Yale University

487 trials monitored

See 35 trials at risk

Heart Failure

1,854 trials monitored

See 95 trials at risk

The purpose of this research study is to understand the biology related to the potential shortcomings of existing anti-aldosterone therapy.

Trial Details

NCT Number	NCT07281014
Lead Sponsor	Yale University Collaborators: Boehringer Ingelheim
Conditions	Heart Failure
Enrollment	21 participants
Start Date	2026-01-27
Primary Completion	2027-08 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2026-08-26